The Kenya Essential Medicines List 2019 is an indispensable guide to the medicines recommended for the management of common conditions in Kenya. It is primarily directed at health care providers and medicines supply managers in the public and non-public health sectors. It should be used together wit...h the current versions of updated national clinical guidelines for those conditions for which such guidelines exist
more
WHO clinical guidelines.
For the first time, WHO has published guidelines to help (primarily) front-line healthcare providers give high-quality, compassionate, and respectful care to children and adolescents (up to age 18) who have or may have experienced sexual abuse, including sexual assault or r...ape.
more
Botswana CPD.
The 6th Government of Botswana/UNFPA Country Programme (2017-2021) is focusing on a transformative development agenda that is universal, inclusive, human rights-based, integrated and anchored in the principle of equality and leaving no one behind, while reaching the furthest left beh...ind first. The country programme will contribute directly to the three outcomes of the United Nations Sustainable Development Framework (2017-2021).
more
Towards Malaria Elimination
NEMLIST | Sixth Edition | February 2016
This report details the nutrition situation in Namibia. It provides information on what needs to be done! The situation calls for a consorted action. Nutrition is everyone’s business.The establishment of the National Alliance for Improved Nutrition (NAFIN) is a positive response to this urgency. N...AFIN is a multi-sectoral and multi-stakeholder association, not for gain.
more
Treating the Patient with Tuberculosis
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
РУКОВОДСТВО ДЛЯ АКТИВИСТОВ ПО ИНСТРУМЕНТАМ ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА ЯНВАРЬ.
CẨM NANG AN TOÀN SINH HỌC PHÒNG XÉT NGHIỆM LAO.
NHÀ XUẤT BẢN Y HỌC HÀ NỘI - 2015.
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition